PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
1881399-1	1991	Supernatants collected from cisplatin-treated macrophages demonstrated enhanced cytotoxicity against actinomycin-D-treated L929 cells and also enhanced the thymocyte proliferation in response to concanavalin A, showing that cisplatin-treated macrophages release interleukin-1 (IL-1) and tumor necrosis factor (TNF) into the culture supernatant.	Cisplatin	28-37	interleukin 1 complex	Mus musculus	262-281	
1881399-1	1991	Supernatants collected from cisplatin-treated macrophages demonstrated enhanced cytotoxicity against actinomycin-D-treated L929 cells and also enhanced the thymocyte proliferation in response to concanavalin A, showing that cisplatin-treated macrophages release interleukin-1 (IL-1) and tumor necrosis factor (TNF) into the culture supernatant.	Cisplatin	224-233	interleukin 1 complex	Mus musculus	262-281	
1881399-3	1991	The release of TNF and IL-1 was observed to be dependent on the dose and duration of cisplatin treatment.	Cisplatin	85-94	interleukin 1 complex	Mus musculus	23-27	
1881399-8	1991	Maximum production and release of IL-1 were observed up to 24 h after cisplatin treatment and then gradually declined.	Cisplatin	70-79	interleukin 1 complex	Mus musculus	34-38	
1881399-9	1991	Freeze-thaw lysates of cisplatin-treated macrophages also showed enhanced IL-1 activity.	Cisplatin	23-32	interleukin 1 complex	Mus musculus	74-78	
1881399-12	1991	These results suggest that cisplatin treatment of murine macrophages also results in increased expression of membrane-associated IL-1 and TNF activity.	Cisplatin	27-36	interleukin 1 complex	Mus musculus	129-133	
3497117-0	1987	Increased release of interleukin-1 from mouse peritoneal macrophages in vitro after cisplatin treatment.	Cisplatin	84-93	interleukin 1 complex	Mus musculus	21-34	
3497117-2	1987	The supernatants collected from the untreated macrophage monolayers show a gradual ten fold increase in the interleukin-1 (IL-1) activity during 30 min to 48 h incubation at 37 degrees C. Supernatants collected from macrophage monolayers treated with 2 micrograms/ml of cis-platin show only a marginal increase in IL-1 activity as compared to untreated monolayers.	Cisplatin	270-280	interleukin 1 complex	Mus musculus	108-127	
3497117-2	1987	The supernatants collected from the untreated macrophage monolayers show a gradual ten fold increase in the interleukin-1 (IL-1) activity during 30 min to 48 h incubation at 37 degrees C. Supernatants collected from macrophage monolayers treated with 2 micrograms/ml of cis-platin show only a marginal increase in IL-1 activity as compared to untreated monolayers.	Cisplatin	270-280	interleukin 1 complex	Mus musculus	123-127	
3497117-3	1987	However, compared to controls, 30 to 40 fold increases in IL-1 activity were measured in supernatants collected from the macrophage monolayers incubated with 5, 10 and 20 micrograms/ml cis-platin at 37 degrees C. The IL-1 activity in supernatants collected from macrophage monolayers treated with cis platin and LPS are also compared.	Cisplatin	297-307	interleukin 1 complex	Mus musculus	58-62	
9673408-2	1998	Similarly, IL-1 is reported to accelerate recovery following myelosuppressive treatment with doxorubicin (AdR), cis-platinum (DDP) and cyclophosphamide (CTx).	Cisplatin	112-124	interleukin 1 complex	Mus musculus	11-15	
9673408-2	1998	Similarly, IL-1 is reported to accelerate recovery following myelosuppressive treatment with doxorubicin (AdR), cis-platinum (DDP) and cyclophosphamide (CTx).	Cisplatin	126-129	interleukin 1 complex	Mus musculus	11-15	
7705961-3	1994	Supernatants collected from macrophages treated with cisplatin and EGTA, nifedipine, TMB-8 or W-7 demonstrated decreased tumor necrosis factor (TNF) and interleukin-1 (IL-1) activity in comparison to supernatants collected from macrophages treated with cisplatin alone.	Cisplatin	53-62	interleukin 1 complex	Mus musculus	153-172	
8514539-3	1993	METHODS AND MATERIALS: IL-1 was administered to C3H/Km mice in combination with fractionated irradiation, or with cyclophosphamide, cisplatin, or 5-fluorouracil (5FU) followed by irradiation.	Cisplatin	132-141	interleukin 1 complex	Mus musculus	23-27	
8514539-7	1993	IL-1 was protective when injected intraperitoneally 24 hr before CY or c-DDP, which were given immediately before the first of five daily radiation dose fractions.	Cisplatin	71-76	interleukin 1 complex	Mus musculus	0-4	
1572101-3	1992	Macrophages treated with cisplatin, LPS, IL-1 and TNF produced released and membrane-associated IL-1 and TNF activity which was significantly enhanced after priming with IFN-gamma.	Cisplatin	25-34	interleukin 1 complex	Mus musculus	41-53	
1572101-3	1992	Macrophages treated with cisplatin, LPS, IL-1 and TNF produced released and membrane-associated IL-1 and TNF activity which was significantly enhanced after priming with IFN-gamma.	Cisplatin	25-34	interleukin 1 complex	Mus musculus	41-45